Current Report Filing (8-k)
November 10 2021 - 5:54AM
Edgar (US Regulatory)
0001799788
false
0001799788
2021-11-09
2021-11-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) November 9, 2021
Greenwich
LifeSciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-39555
|
|
20-5473709
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.
R. S. Employer
Identification
No.)
|
3992
Bluebonnet Dr, Building 14
Stafford,
TX 77477
(Address
of principal executive offices, including ZIP code)
(832)
819-3232
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, $0.001 par value
|
|
GLSI
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
Greenwich
LifeSciences, Inc. (the “Company”) intends to conduct meetings with third parties in which its corporate slide presentation
(“Company Presentation”) will be presented. The Company Presentation is attached to this Current Report on Form 8-K as Exhibit
99.1 and incorporated into this Item 7.01 by reference. In addition, the Company released a press release attached to this Current
Report on Form 8-K as Exhibit 99.2 and incorporated into this Item 7.01 by reference.
In
accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01 of this Current Report on Form 8-K
and the exhibit attached hereto are deemed to be “furnished” and shall not be deemed “filed” for the purpose
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall
such information and exhibit be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Greenwich
LifeSciences, Inc.
|
|
|
|
Date:
November 10, 2021
|
By:
|
/s/
Snehal Patel
|
|
|
Snehal
Patel
|
|
|
Chief
Executive Officer
|
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From May 2023 to May 2024